Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway

Aging (Albany NY). 2020 May 18;12(10):9515-9533. doi: 10.18632/aging.103225. Epub 2020 May 18.

Abstract

Despite decades of research into the pathology mechanisms of Parkinson's disease (PD), disease-modifying therapy of PD is scarce. Thus, searching for new drugs or more effective neurosurgical treatments has elicited much interest. Clioquinol (CQ) has been shown to have therapeutic benefits in rodent models of neurodegenerative disorders. However, it's neuroprotective role and mechanisms in PD primate models and PD patients, especially in the advanced stages, are not fully understood. Furthermore, issues such as spontaneous recovery of motor function and high symptom variability in different monkeys after the same toxic protocol, has not been resolved before the present study. In this study, we designed a chronic and long-term progressive protocol to generate a stabilized PD monkey model showed with classic motor and non-motor deficits, followed by treatment analysis of CQ. We found that CQ could remarkably improve the motor and non-motor deficits, which were based on the reduction of iron content and ROS level in the SN and further improvement in pathology. Meanwhile, we also showed that ferroptosis was probably involved in the pathogenesis of PD. In addition, the study shows a positive effect of CQ on AKT/mTOR survival pathway and a blocking effect on p53 medicated cell death in vivo and in vitro.

Keywords: Parkinson’s disease; clioquinol; ferroptosis; iron; monkey.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Animals
  • Clioquinol / pharmacology*
  • Disease Models, Animal
  • Haplorhini
  • Motor Activity / drug effects*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Proto-Oncogene Proteins c-akt / drug effects*
  • Signal Transduction / drug effects
  • TOR Serine-Threonine Kinases / drug effects*

Substances

  • Clioquinol
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases